ERAS Share Price Performance
US$14.97
13.45 (884.87%)
29.5% overvalued intrinsic discount
US$11.56
Fair Value
Price US$14.97
Vestra US$11.56
Fair ValueUS$11.56
Share Pricen/a
Erasca, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ERAS Community Narratives
VE
Fair Value US$11.56 29.5% overvalued intrinsic discount
Erasca, Inc. (ERAS): The RAS Specialist – Scaling the Precision Oncology Peak
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Erasca, Inc. (ERAS): The RAS Specialist – Scaling the Precision Oncology Peak
The current narrative for Erasca, Inc. (ERAS) as of March 20, 2026, is one of a "Clinical Breakout" as the company moves into its most catalyst-heavy year to date.Read more
31
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Trending Discussion
Recently Updated Narratives
VE
Erasca, Inc. (ERAS): The RAS Specialist – Scaling the Precision Oncology Peak
Fair Value: US$11.56 29.5% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Erasca, Inc. Key Details
About ERAS
- Founded
- 2018
- Employees
- 103
- CEO
- WebsiteView website
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
